The aim of this study is to develop a personalized risk management guideline for carriers of the pathogenic variants of BRCA1 and BRCA2 who underwent BCT for unilateral early-stage breast cancer taking into account the patient characteristics and tumor prognostic parameters as well as systemic treatment received. Here, BRCA1 is linked to breast cancer.